24Jan 2025
GLP-1 RA Therapy Benefits LVAD Patients

GLP-1 RA Therapy Benefits LVAD Patients

In the study of 40 LVAD patients treated with GLP-1 receptor agonists (GLP-1 RAs), therapy significantly reduced weight (116 vs. 110 kg, p<0.001), HbA1c (6.4 vs. 5.7, p=0.003), and NT-proBNP levels (810 vs. 732 pg/mL, p=0.04) over 1 year. Adverse events were minimal, with no therapy interruptions or significant cannula position changes. GLP-1 RA therapy shows promise in improving cardiometabolic outcomes and may support transplant candidacy in LVAD patients.

  • #cardiology

Like

Save

Share